MARIETTA, Ga., March 17, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that Deborah Dean, Executive Vice President, and Frank Burrows, Vice President, will represent the Company at the 3rd Annual Regen Med Investor Day in New York, New York. The presentation will be conducted "investor conference" style, with a 5-minute introduction by the presenter, followed by a 10 minute 'fireside chat' discussion on stage with a leading research analyst. The MiMedx timeslot is scheduled for Wednesday, March 25th, at 10:50 a.m. EDT, at the Metropolitan Club. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
Organized by the Alliance for Regenerative Medicine (ARM), in partnership with leading financial firms Maxim Group and Piper Jaffray, this one-day investor conference focuses exclusively on the regenerative medicine and advanced therapies sector. The event includes clinical and commercial experts who will be on-hand to address specific questions regarding the outlook for the industry, as well as offer insight into how regenerative medicine products could impact the standard of care in key therapeutic areas. The program will include talks by key opinion leaders in the industry, life science investment experts and analysts, as well as presentations by more than 30 leading companies from across the globe.
About MiMedx
MiMedx® is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 350,000 allografts to date for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mimedx-to-present-at-3rd-annual-regen-med-investor-day-300051719.html
SOURCE MiMedx Group, Inc.
